Podcast

Health and medical research have featured prominently in Western Australia’s 2025-26 Budget, with investment in manufacturing infrastructure and industry clinical trials.

The company has submitted an application to the TGA for registration of twice-yearly lenacapavir for pre-exposure prophylaxis to prevent the acquisition of HIV.

The end of an era with Richard Vines, who co-founded Rare Cancers Australia (RCA) with his wife Kate, stepping down as the organisation’s chair.

In the final instalment of a four-part series comparing health systems and financing in Australia and the US, we demonstrate how even a significant reform of medicine pricing in the US will have almost no impact on health spending in that country.

Amplia Therapeutics (ASX:ATX) has provided an update on the ongoing ACCENT trial investigating its FAK inhibitor narmafotinib in advanced pancreatic cancer.

New Zealand's Deputy Prime Minister and Associate Health Minister, David Seymour, has announced regulatory changes to make melatonin and medicinal psilocybin more accessible.

Imugene (ASX:IMU) has received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for its patent application number that protects its oncolytic virotherapy CF33-CD19 and its combination with CD19 targeting CAR-T cell therapies.

CLINUVEL (ASX:CUV) has announced final results from its Phase 2 pilot study evaluating SCENESSE (afamelanotide) as a monotherapy in patients with the depigmentation disorder vitiligo.

The US FDA's approval of CSL's ANDEMBRY (garadacimab) for hereditary angioedema provides another opportunity to compare patient access to innovative treatments in the US and Australia.

In an address during the recent election campaign, Prime Minister Anthony Albanese held a Medicare card and said, "But the most important number in this equation is one. One card guarantees it all. One card covers it all. Not your credit card - your Medicare card."

Montu, a provider of telehealth services, has been invited to contribute to the Productivity Commission’s national inquiry into data, digital technology, and delivering quality care more efficiently.

Pharmac’s board has appointed Canadian Natalie McMurtry to succeed Sarah Fitt as the organisation's new chief executive.